Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$3.2MCash on Hand
5.6mo Cash Runway
Follow BDRX by emailGet an email when BDRX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about BDRX, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 9, 2026 ·
Clinical trial Serenta Phase 3 trial of eRapa in FAP has enrolled 112 of an expected 168 participants. Futility analysis could come early in 2027 and database lock around end of 2027, sooner than originally anticipated. A pre-IND meeting with the FDA for MTX240 is scheduled for December 10, 2026. Form 6-K · SEC filing · Press release
Oct 14, 2026 ·
Listing Biodexa will change its ADS ratio from one ADS for 50 ordinary shares to one ADS for 400 ordinary shares, effective on or about October 26, 2026. Holders must exchange every eight old ADSs for one new ADS, with no fractional ADSs issued. Form 424B3 · SEC filing
Oct 14, 2026 ·
Listing Biodexa will change its ADS ratio from 1 ADS for 50 ordinary shares to 1 ADS for 400, effective on or about October 26, 2026. Holders must exchange every eight old ADSs for one new ADS, with no fractional ADSs issued. Form 424B3 · SEC filing
Oct 14, 2026 ·
Listing Biodexa will change its ADS ratio from one ADS for 50 ordinary shares to one ADS for 400 ordinary shares, effective on or about October 26, 2026. Holders must exchange eight old ADSs for one new ADS, with no fractional ADSs issued. Form 424B3 · SEC filing
Oct 14, 2026 ·
Listing Biodexa will change its ADS ratio from one ADS for 50 ordinary shares to one ADS for 400, effective on or about October 26, 2026. ADS holders must exchange eight old ADSs for one new ADS, with fractions sold and proceeds distributed. Form 424B3 · SEC filing
Oct 14, 2026 ·
Restructuring Biodexa will change its ADS ratio from one ADS for 50 ordinary shares to one ADS for 400 ordinary shares, around October 26, 2026. ADS holders must exchange eight old ADSs for one new ADS, a one-for-eight reverse ADS split. Fractions will be sold and proceeds distributed. Form 424B3 · SEC filing
Oct 14, 2026 ·
Listing Biodexa will change its ADS ratio from one ADS for 50 ordinary shares to one ADS for 400, effective on or about October 26, 2026. Holders must exchange eight old ADSs for one new ADS, with no fractional ADSs issued. Form 424B3 · SEC filing
Oct 14, 2026 ·
Listing Biodexa will change its ADS ratio from one ADS for 50 ordinary shares to one ADS for 400 shares, effective on or about October 26, 2026. Holders must exchange eight old ADSs for one new ADS, with fractions sold and proceeds distributed. Form 424B3 · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jul 2030 · Phase 3 · Recruiting · Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
BDRX holds $3.2M in cash and short-term investments and burns about $1.7M/quarter from operations,
an estimated runway of 5.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:0 · Low
Cash runway not available
Shelf registration (F-3, Sep 2025) +10
Raised after last reported balance sheet (Jul 2026) -10
Share count 225,817,808,922 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full BDRX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BDRX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.